Welcome to our dedicated page for Elanco Animal Health news (Ticker: ELAN), a resource for investors and traders seeking the latest updates and insights on Elanco Animal Health stock.
Elanco Animal Health develops, manufactures and markets animal health products for farm animals and pets. News about ELAN commonly covers operating and financial results, product launches in pet health and livestock health, and regulatory actions involving animal medicines and parasite-control products.
Company updates also include capital-structure disclosures, investor conference presentations, and governance changes tied to Elanco's board and public-company operations. Product-specific developments have included the Advantage brand for dogs and emergency-authorized livestock treatments such as Negasunt Powder and Tanidil.
Elanco Animal Health (NYSE: ELAN) will attend the Stifel 2022 Jaws and Paws Conference on June 1, 2022. CEO Jeff Simmons is scheduled to participate in a fireside chat at 3:00 p.m. ET. A live audio webcast of the event will be accessible on Elanco’s investor website, with a replay available for 30 days.
Elanco Animal Health reported Q1 2022 revenue of $1,225 million, a 1% decline year-over-year, but a 2% increase in constant currency. Net income stood at $48 million, up from a $61 million loss in Q1 2021. Adjusted EPS was $0.36, slightly down from $0.37. The company updated its full-year revenue guidance to a range of $4,700-$4,755 million, affected by foreign exchange rates. A strategic alliance with Royal DSM for Bovaer, a methane-reducing product, aims to generate significant future revenue. Despite some market pressures, Elanco remains confident in its growth strategy.
Elanco and Royal DSM have formed a strategic alliance to enhance sustainability in livestock farming by developing the methane-reducing product, Bovaer®, in the U.S. Elanco gains exclusive rights to commercialize the product, which has the potential for over US$200 million in annual revenue in the U.S. alone, contributing to the Global Methane Pledge goal of a 30% emission reduction by 2030. Royal DSM will benefit from royalty income and increased production capacity, promoting a significant environmental impact through reduced methane emissions from cattle.
Elanco Animal Health Incorporated (NYSE: ELAN) is set to announce its first quarter 2022 financial results on May 9, 2022, at 8:00 a.m. eastern time. The announcement will be accompanied by a conference call for investors and media, providing insights into the company's performance. The details of the call will be accessible via a live webcast on Elanco’s website. As a global leader in animal health, Elanco focuses on innovating products and services to improve animal welfare and create value for various stakeholders.
Elanco Animal Health has announced plans for a new global headquarters in Indianapolis, featuring a 220,000 square foot structure. The campus aims to promote innovation and sustainability, incorporating environmentally-friendly materials and designs. The project will rejuvenate a long-idle site, expanding White River State Park and enhancing local connectivity. Elanco’s initiative is supported by strategic partnerships, including funding for new ventures. Construction is expected to take 2-3 years, influenced by incentive packages from the State and City.
Elanco Animal Health announced a successful tender offer for its 4.272% Senior Notes due 2023, with about $406.4 million (54.19% of total principal) tendered by the April 11, 2022 deadline. The company increased the tender cap from $250 million to $406.4 million. Validly tendered notes will receive a total consideration of $1,035 per $1,000 principal amount. The offer expires on April 25, 2022, and all conditions remain unchanged except for the tender cap increase.
Elanco Animal Health and Ginkgo Bioworks have launched BiomEdit, a new company focused on microbiome innovations for animal health. BiomEdit aims to develop probiotics and other solutions addressing urgent needs in livestock health, including antibiotic resistance. With an initial funding of $40 million, BiomEdit will operate independently, utilizing Elanco’s microbiome R&D expertise and intellectual property. This strategic separation allows Elanco to concentrate more effectively on its late-stage pet health pipeline while facilitating the growth of BiomEdit in the animal health sector.
Elanco Animal Health Incorporated (NYSE: ELAN) has initiated a cash tender offer for up to $250 million in aggregate principal amount of its 4.272% Senior Notes due 2023. The offer, detailed in the Offer to Purchase dated March 29, 2022, will expire at midnight location value="LU/us.ny.nyc"New York City time on April 25, 2022. Holders who tender their notes by April 11, 2022, will be eligible for a total consideration of $1,035 per $1,000 principal amount. The offer is subject to certain conditions.
Elanco Animal Health (NYSE: ELAN) is expanding its shared value initiative in Sub-Saharan Africa, focused on improving livestock health and sustainability for small-scale farmers. The new project, MAHABA, aims to tackle tick infestations affecting up to 98% of cattle in Uganda and 80% in Nigeria. This initiative follows the East Africa Growth Accelerator and involves partnerships with GALVmed and the Bill & Melinda Gates Foundation. Elanco's commitment aligns with its 2030 sustainability goals, enhancing food security for local communities.
Elanco Animal Health reported a full-year 2021 revenue of $4,765 million, marking a 46% increase, largely due to Bayer Animal Health product integration. Despite a 2% decline in Q4 revenue to $1,113 million, adjusted EPS rose 75% to $0.21. Guidance for 2022 anticipates revenue between $4,745 million and $4,800 million, with adjusted EPS projected at $1.18 to $1.24. Significant innovation is expected, with $120 to $160 million in innovation revenue and 7 anticipated product approvals. Cost-cutting measures, including a reduction of 380 positions, aim to improve efficiency.